Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Andrew X. Zhu is a Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital. His clinical practice focuses on medical and multidisciplinary management of patients with gastrointestinal cancers including liver, bile duct, colorectal, pancreatic, gastroesophageal, and neuroendocrine cancers. Dr. Zhu is an internationally recognized expert in hepatocellular carcinoma and cholangiocarcinoma. His clinical and research interests have focused on developing innovative therapies for hepatobiliary cancers, identifying novel molecular markers and genetic mutations, and dissecting the molecular mechanisms of drug resistance to targeted therapy in hepatobiliary cancers. Dr. Zhu serves on the Hepatobiliary Cancer Committee of the National Comprehensive Cancer Network (NCCN), the Grants Selection Committee of the American Society of Clinical Oncology (ASCO), the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee (GISC), the American Joint Committee on Cancer (AJCC) Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases (AASLD), and the Clinical Advisory Board of the Cholangiocarcinoma Foundation.
As the Director of Liver Cancer Research at Massachusetts General Hospital, Dr. Zhu oversees the clinical and translational research program in hepatobiliary cancers. His major focus of research is in developing more effective therapies for hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs) through phase I, II and III clinical trials with several strategies: 1. Test novel molecularly targeted agents with unique mechanisms of action; 2. Use different targeted agents in combination to inhibit critical pathways of HCC/BTC carcinogenesis; 3. Examine immune therapy alone or in combination with other agents in HCC/BTCs; and 4. Assess novel radiation therapy (i.e. proton) either alone or in combination with targeted/immune therapy.
The second area of his research interests is highly complementary and is directed at the development of novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area of his research is to define and characterize known or novel mutations/molecular signatures in HCC and BTCs to assess their potential correlation with clinical outcomes, as therapeutic targets, and drug resistance mechanisms.
View my most recent publications at PubMed
Selected publications from more than 200 peer-reviewed articles.
Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA, 2014, 312(1):57-67. doi:10.1001/jama.2014.7189. PMID: 25058218
Zhu AX, Park JO, Ryoo BY,Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TEF, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: results from the randomised phase 3 REACH study. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. PMID: 26095784
Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Graus Porta D, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29. PMID: 28034880
Investigators at the Massachusetts General Hospital Cancer Center have identified the first genetic mechanisms conferring acquired resistance to a promising group of targeted cancer drugs.
Investigators at the MGH Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.
Back to Top